Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Clinical Significance of Combining Preoperative and Postoperative Albumin-Bilirubin Score in Colorectal Cancer: Doyoun Kim, Jae-Hoon Lee, Eun-Suk Cho, Su-Jin Shin, Hye Sun Lee, Hwa-Hee Koh, Kang Young Lee, Jeonghyun Kang; Cancer Res Treat. 2023;55(4):1261-1269. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2022.1444

Abstract PDF Supplementary Material PubReader ePub

Purpose
Albumin-bilirubin (ALBI) score is a well-known prognostic factor for various diseases, including colorectal cancer (CRC). However, little is known about the significance of postoperative ALBI score changes in patients with CRC.
Materials and Methods
A total of 723 patients who underwent surgery were enrolled. Preoperative ALBI (ALBI-pre) and postoperative ALBI (ALBI-post) scores were divided into low and high score groups. ALBI-trend was defined as a combination of four groups comprising the low and high ALBI-pre and ALBI-post score groups. Kaplan-Meier survival curves were used to compare the overall survival (OS) between the different ALBI groups. The Cox proportional hazards model was used to examine the independent relevant factors of OS. Stratification performance was compared between the different ALBI groupings using Harrell’s concordance index (C-index).
Results
ALBI-pre, ALBI-post, and ALBI-trend score groups were significant prognostic factors of OS in the univariable analysis. However, multivariable analysis showed that ALBI-trend was an independent prognostic factor while ALBI-pre and ALBI-post were not. The C-index of ALBI-trend (0.622; 95% confidence interval [CI], 0.587 to 0.655) was higher than that of ALBI-pre (0.589; 95% CI, 0.557 to 0.621; bootstrap mean difference, 0.033; 95% CI, 0.013 to 0.057) and ALBI-post (0.575; 95% CI, 0.545 to 0.605; bootstrap mean difference, 0.047; 95% CI, 0.024 to 0.074).
Conclusion
Combining ALBI-pre and ALBI-post scores is an independent prognostic factor of OS and shows superior predictive power compared to ALBI-pre or ALBI-post alone in patients with CRC.

Citations

Citations to this article as recorded by

Comparing laboratory toxicity of selective intra-arterial radionuclide therapy for primary and metastatic liver tumors: resin versus glass microspheres
Başak Soydaş-Turan, M. Fani Bozkurt, Gonca Eldem, Bora Peynircioglu, Omer Ugur, Bilge Volkan-Salanci
Annals of Nuclear Medicine.2025; 39(4): 373. CrossRef
Improvement of Hypoalbuminemia and Hepatic Reserve after Stent Placement for Postsurgical Portal Vein Stenosis
Naoya Kinota, Daisuke Abo, Ryo Morita, Koji Yamasaki, Takaaki Fujii, Daisuke Kato, Tasuku Kimura, Yusuke Sakuhara, Kazufumi Okada, Isao Yokota, Tatsuya Orimo, Tatsuhiko Kakisaka, Toru Nakamura, Satoshi Hirano, Kazuyuki Minowa, Kohsuke Kudo
Journal of Vascular and Interventional Radiology.2025; 36(4): 616. CrossRef
Gastrointestinal tumors of the small bowel: prognostic roles of tumor stage and inflammatory markers
Mehmet Torun, Sevil Özkan, Deniz Kol Özbay, Erkan Özkan
Anatolian Current Medical Journal.2025; 7(2): 164. CrossRef
Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery
Li Chen, Chunlei Tan, Qingwen Li, Zhibo Ma, Meng Wu, Xiaosheng Tan, Tiangen Wu, Jinwen Liu, Jing Wang
Heliyon.2023; 9(11): e21772. CrossRef

3,658 View
182 Download
3 Web of Science
4 Crossref

Genitourinary cancer

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma: Se Un Jeong, Hee Sang Hwang, Ja-Min Park, Sun Young Yoon, Su-Jin Shin, Heounjeong Go, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho; Cancer Res Treat. 2023;55(1):231-244. Published online March 2, 2022; DOI: https://doi.org/10.4143/crt.2021.1526

Abstract PDF Supplementary Material PubReader ePub

Purpose
Tyrosine kinase inhibitors (TKI) targeting vascular endothelial growth factor receptor (VEGFR) signaling pathways have been used for metastatic clear cell renal cell carcinoma (mCCRCC), but resistance to the drug develops in most patients. We aimed to explore the underlying mechanism of the TKI resistance with regard to programmed death-ligand 1 (PD-L1) and to investigate signaling pathway associated with the resistant mechanism.
Materials and Methods
To determine the mechanism of resistance, 10 mCCRCC patients from whom tumor tissues were harvested at both the pretreatment and the TKI-resistant post-treatment period were included as the discovery cohort, and their global gene expression profiles were compared. A TKI-resistant renal cancer cell line was established by long-term treatment with sunitinib.
Results
Among differentially expressed genes in the discovery cohort, increased PD-L1 expression in post-treatment tissues was noted in four patients. Pathway analysis showed that PD-L1 expression was positively correlated with the mammalian target of rapamycin (mTOR) signaling pathway. The TKI-resistant renal cancer cells showed increased expression of PD-L1 and mTOR signaling proteins and demonstrated aggressive tumoral behaviour. Treatment with mTOR inhibitors down-regulated PD-L1 expression and suppressed aggressive tumoral behaviour, which was reversed with stimulation of the mTOR pathway.
Conclusion
These results showed that PD-L1 expression may be increased in a subset of VEGFR-TKI–resistant mCCRCC patients via the mTOR pathway.

Citations

Citations to this article as recorded by

Bioinformatics Identification of Lactate‐Associated Genes in Hepatocellular Carcinoma: G6PD's Role in Immune Modulation
Hao‐ran Qu, Chao‐qun Wang, Su‐juan Sun, Wen‐wen Zhang, Cheng‐hao Liu, Xuan‐shuang Du, Yao‐yi‐ao Shu, Xi‐cheng Wang, Qin Pan, Feng‐ling Luo, Hong‐yan Wu, Xiao‐lian Zhang, Min Liu
Cancer Medicine.2025;[Epub] CrossRef
IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma
Se Un Jeong, Ja-Min Park, Sun Young Yoon, Hee Sang Hwang, Heounjeong Go, Dong-Myung Shin, Hyein Ju, Chang Ohk Sung, Jae-Lyun Lee, Gowun Jeong, Yong Mee Cho
Investigative and Clinical Urology.2024; 65(1): 84. CrossRef
Targeting apoptosis in clear cell renal cell carcinoma
Adam Kowalewski, Jędrzej Borowczak, Mateusz Maniewski, Karol Gostomczyk, Dariusz Grzanka, Łukasz Szylberg
Biomedicine & Pharmacotherapy.2024; 175: 116805. CrossRef
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian-Bogdan Tigu, Raluca Munteanu, Cristian-Silviu Moldovan, David Kegyes, Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics
Yunxia Wang, Xiaolin Liu, Luyao Gong, Weihong Ding, Wenjing Hao, Yeheng Peng, Jun Zhang, Weimin Cai, Yuan Gao
British Journal of Pharmacology.2023; 180(23): 2937. CrossRef
Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series
Luigi Liguori, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, Francesco Sabbatino
Biomedicines.2023; 11(11): 2974. CrossRef

6,420 View
227 Download
6 Crossref

Gastrointestinal cancer

Association of Body Mass Index with Survival in Asian Patients with Colorectal Cancer: Sangwon Lee, Dong Hee Lee, Jae-Hoon Lee, Su-Jin Shin, Hye Sun Lee, Eun Jung Park, Seung Hyuk Baik, Kang Young Lee, Jeonghyun Kang; Cancer Res Treat. 2022;54(3):860-872. Published online October 15, 2021; DOI: https://doi.org/10.4143/crt.2021.656

Abstract PDF Supplementary Material PubReader ePub

Purpose
The clinical significance of body mass index (BMI) on long-term outcomes has not been extensively investigated in Asian patients with colorectal cancer (CRC). This study aims to describe the association between BMI and survival, plus providing BMI cut-off value for predicting prognosis in CRC patients.
Materials and Methods
A total of 1,182 patients who had undergone surgery for stage I-III CRC from June 2004 to February 2014 were included. BMI was categorized into four groups based on the recommendation for Asian ethnicity. The optimal BMI cut-off value was determined to maximize overall survival (OS) difference.
Results
In multivariable analysis, underweight BMI was significantly associated with poor OS (hazard ratio [HR], 2.38; 95% confidence interval [CI], 1.55 to 3.71; p < 0.001) and obese BMI was associated with better OS (HR, 0.72; 95% CI, 0.53 to 0.97; p=0.036) compared with the normal BMI. Overweight and obese BMI were associated with better recurrence-free survival (HR, 0.64; 95% CI, 0.42 to 0.99; p=0.046 and HR, 0.58; 95% CI, 0.38 to 0.89; p=0.014, respectively) compared with the normal BMI group. BMI cutoff value was 20.44 kg/m². Adding the BMI cutoff value to cancer staging could increase discriminatory performance in terms of integrated area under the curve and Harrell’s concordance index.
Conclusion
Compared to normal BMI, underweight BMI was associated with poor survival whereas obese BMI was associated with better survival. BMI cut-off value of 20.44 kg/m² is a useful discriminator in Asian patients with CRC.

Citations

Citations to this article as recorded by

Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies
H. Wen, G. Deng, X. Shi, Z. Liu, A. Lin, Q. Cheng, J. Zhang, P. Luo
ESMO Open.2024; 9(3): 102241. CrossRef
Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting
Kirati Kengkla, Surakit Nathisuwan, Warunsuda Sripakdee, Pirun Saelue, Kwanruethai Sengnoo, Aumkhae Sookprasert, Suphat Subongkot
JCO Global Oncology.2024;[Epub] CrossRef
Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis
Nerea Becerra‐Tomás, Georgios Markozannes, Margarita Cariolou, Katia Balducci, Rita Vieira, Sonia Kiss, Dagfinn Aune, Darren C. Greenwood, Laure Dossus, Ellen Copson, Andrew G. Renehan, Martijn Bours, Wendy Demark‐Wahnefried, Melissa M. Hudson, Anne M. Ma
International Journal of Cancer.2024; 155(3): 400. CrossRef
Low muscle mass-to-fat ratio is an independent factor that predicts worse overall survival and complications in patients with colon cancer: a retrospective single-center cohort study
Jiabao Tang, Jingwen Xu, Xiaohua Li, Chun Cao
Annals of Surgical Treatment and Research.2024; 107(2): 68. CrossRef
Comment on “Dense Tumor‐Infiltrating Lymphocytes (TILs) in Liver Metastasis From Colorectal Cancer Are Related to Improved Overall Survival”
Fuji Lai, Sheng Li, Zhonglei Shen
Journal of Surgical Oncology.2024;[Epub] CrossRef
Obesity, the Adipose Organ and Cancer in Humans: Association or Causation?
Elisabetta Trevellin, Silvia Bettini, Anna Pilatone, Roberto Vettor, Gabriella Milan
Biomedicines.2023; 11(5): 1319. CrossRef
Higher body mass index was associated with better prognosis in diabetic patients with stage II colorectal cancer
Xiao-Yu Liu, Bing Kang, Yu-Xi Cheng, Chao Yuan, Wei Tao, Bin Zhang, Zheng-Qiang Wei, Dong Peng
BMC Cancer.2022;[Epub] CrossRef
Preoperative carcinoembryonic antigen to body mass index ratio contributes to prognosis prediction in colorectal cancer
Jia Xiang, Mengyao Ding, Jixing Lin, Tianhui Xue, Qianwen Ye, Bing Yan
Oncology Letters.2022;[Epub] CrossRef

7,895 View
144 Download
8 Web of Science
8 Crossref

Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma: Yeseul Kim, Seong Sik Bang, Seungyun Jee, Sungeon Park, Su-Jin Shin, Kiseok Jang; Cancer Res Treat. 2020;52(2):481-491. Published online October 24, 2019; DOI: https://doi.org/10.4143/crt.2019.370

Abstract PDF Supplementary Material PubReader ePub

Purpose
Mesenchymal epithelial transition (MET) is a proto-oncogene that encodes a heterodimeric transmembrane receptor tyrosine kinase for the hepatocyte growth factor. Aberrant MET signaling has been described in several solid tumors—especially non-small cell lung cancer— and is associated with tumor progression and adverse prognosis. As MET is a potential therapeutic target, information regarding its prevalence and clinicopathological relevance is crucial.
Materials and Methods
We investigated MET expression and gene amplification in 113 gallbladder cancers using tissue microarray. Immunohistochemistry was used to evaluate MET overexpression, and silver/fluorescence in situ hybridization (ISH) was used to assess gene copy number.
Results
MET overexpression was found in 37 cases of gallbladder carcinoma (39.8%), and gene amplification was present in 17 cases (18.3%). MET protein expression did not correlate with MET amplification. MET amplification was significantly associated with aggressive clinicopathological features, including high histological grade, advanced pT category, lymph node metastasis, and advanced American Joint Committee on Cancer stage. There was no significant correlation between any clinicopathological factors and MET overexpression. No difference in survival was found with respect to MET overexpression and amplification status.
Conclusion
Our data suggested that MET might be a potential therapeutic target for targeted therapy in gallbladder cancer, because MET amplification was found in a subset of tumors associated with adverse prognostic factors. Detection of MET amplification by ISH might be a useful predictive biomarker test for anti-MET therapy.

Citations

Citations to this article as recorded by

Genomic and molecular landscape of gallbladder cancer elucidating pathogenic mechanisms novel therapeutic targets and clinical implications
Manishankar Kumar, Arun Kumar, Abhinav Srivastav, Ashok Ghosh, Dhruv Kumar
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis.2025; 830: 111896. CrossRef
Structure based multi-targeted screening, docking, DFT and simulation of anticancer natural compounds against gallbladder cancer
Suchitra Singh, Janhavi Yadav, Surbhi Singh, Sumanta Kumar Sahu, Puneet Puneet, Royana Singh
In Silico Pharmacology.2025;[Epub] CrossRef
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature
Pei Yuan, Xuemin Xue, Tian Qiu, Jianming Ying
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
The Oncologist.2024; 29(8): e1051. CrossRef
Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer
Qiu-Xiao Yu, Ping-Ying Fu, Chi Zhang, Li Li, Wen-Ting Huang
World Journal of Gastrointestinal Surgery.2024; 16(5): 1395. CrossRef
Which therapy in biliary tract cancer? Review of main concerns in diagnosis and choice of therapy in advanced setting, current standard, and new options
Ester Oneda, Serena Astore, Laura Gandolfi, Laura Melocchi, Alberto Zaniboni
Expert Opinion on Pharmacotherapy.2024; 25(13): 1807. CrossRef
Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome
Wei Yin, Wei Liu, Ming Guo, Zhenya Tang, Gokce Toruner, Melissa Robinson, Joanne Cheng, Shimin Hu, L. Jeffrey Medeiros, Guilin Tang
Experimental and Molecular Pathology.2021; 118: 104572. CrossRef
Novel biomarkers for the diagnosis and prognosis of gallbladder cancer
Hong Ze Lin, Tao Zhang, Ming Yu Chen, Ji Liang Shen
Journal of Digestive Diseases.2021; 22(2): 62. CrossRef
A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification
Hongna Sun, Xiaofen Li, Shuang Dai, Xudong Shen, Meng Qiu
Precision Clinical Medicine.2021; 4(3): 209. CrossRef
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
Cancers.2021; 13(22): 5671. CrossRef
Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas
Jeremy Augustin, Caroline Gabignon, Aurélie Scriva, Laëtitia Menu, Claire Calmel, Olivier Scatton, François Paye, Jean-François Fléjou, Françoise Praz, Pascale Cervera, Dominique Wendum
Virchows Archiv.2020; 477(1): 33. CrossRef
Targeted-gene sequencing of an undifferentiated gallbladder carcinoma: a case report
Ying Xiao, Canhong Xiang, Di Yang, Benqi Zhao, Yong Li, Hongfang Yin
Diagnostic Pathology.2020;[Epub] CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef

11,060 View
225 Download
13 Web of Science
13 Crossref

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma: Jee Hung Kim, Su-Jin Shin, Soo Jin Heo, Eun-Ah Choe, Chang Gon Kim, Minkyu Jung, Ki Chang Keum, Jin Sook Yoon, Sung Chul Lee, Sang Joon Shin; Cancer Res Treat. 2018;50(4):1238-1251. Published online December 28, 2017; DOI: https://doi.org/10.4143/crt.2017.534

Abstract PDF Supplementary Material PubReader ePub

Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood ofrecurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression-free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy.
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)‒negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival.
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.

Citations

Citations to this article as recorded by

Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery
Louis Cappelli, Mehak M. Khan, Carol L. Shields, Sara E. Lally, Muhammad Sharif, Haisong Liu, Yingxuan Chen, Jade Park, Tingting Zhan, Wenyin Shi
American Journal of Ophthalmology.2025; 271: 417. CrossRef
Genetic landscape of uveal melanoma in Southeast Asia: high 1q gains and unique patterns of metastasis risk
Chuanfei Chen, Mona Meng Wang, Alvin Soon Tiong Lim, Evelyn Yee Hsieh Heng, Sim Leng Tien, Sunny Yu Shen, Gavin Siew Wei Tan, Jason Yongsheng Chan, Anita Sook Yee Chan
Eye and Vision.2025;[Epub] CrossRef
Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives
Merve Kulbay, Emily Marcotte, Raheem Remtulla, Tsz Hin Alexander Lau, Manuel Paez-Escamilla, Kevin Y. Wu, Miguel N. Burnier
Biomedicines.2024; 12(8): 1758. CrossRef
Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study
Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard
Cancers.2024; 16(19): 3346. CrossRef
Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma
Binghua Yang, Yuxia Fan, Renlong Liang, Yi Wu, Aiping Gu
BMC Ophthalmology.2023;[Epub] CrossRef
Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result
Yaping Su, Xiaolin Xu, Fang Wang, Panli Zuo, Qinghua Chen, Wenbin Wei, Junfang Xian
Journal of Computer Assisted Tomography.2023; 47(1): 151. CrossRef
Uveal melanoma pathobiology: Metastasis to the liver
Prisca Bustamante, Léo Piquet, Solange Landreville, Julia V. Burnier
Seminars in Cancer Biology.2021; 71: 65. CrossRef
Malignant uveal melanoma with metastatic recurrence to the pancreas: A case report
Wei‐Chun Weng, Tzung‐Jiun Tsai, Wen‐Chi Chen, Jin‐Shiung Cheng, Wei‐Chih Sun
Advances in Digestive Medicine.2021; 8(3): 178. CrossRef
Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort
Paula Silva‐Rodríguez, Manuel Bande, Daniel Fernández‐Díaz, Nerea Lago‐Baameiro, María Pardo, María José Blanco‐Teijeiro, Fernando Domínguez, Lourdes Loidi, Antonio Piñeiro
Acta Ophthalmologica.2021;[Epub] CrossRef
Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort
Laura Ling Ying Tan, Jiancheng Hong, Wei Lin Goh, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Anita Sook Yee Chan, Jason Yongsheng Chan
Scientific Reports.2020;[Epub] CrossRef
ЕФЕКТИВНІСТЬ РАДІОХВИЛЬОВОЇ (3,8 МГЦ) БЛОКЕКСЦИЗІЇ МЕЛАНОМИ ЦИЛІОХОРІОЇДАЛЬНОЇ ЛОКАЛІЗАЦІЇ
O. V. Khomyakova
Здобутки клінічної і експериментальної медицини.2020; (3): 173. CrossRef

10,857 View
231 Download
13 Web of Science
11 Crossref

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only: Su-Jin Shin, Hosub Park, You-Na Sung, Changhoon Yoo, Dae Wook Hwang, Jin-hong Park, Kyu-pyo Kim, Sang Soo Lee, Baek-Yeol Ryoo, Dong-Wan Seo, Song Cheol Kim, Seung-Mo Hong; Cancer Res Treat. 2018;50(4):1175-1185. Published online December 20, 2017; DOI: https://doi.org/10.4143/crt.2017.494

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pancreatic cancer associated double primary tumors are rare and their clinicopathologic characteristics are not well elucidated.
Materials and Methods
Clinicopathologic factors of 1,352 primary pancreatic cancers with or without associated double primary tumors were evaluated.
Results
Of resected primary pancreatic cancers, 113 (8.4%) had associated double primary tumors, including 26 stomach, 25 colorectal, 18 lung, and 13 thyroid cancers. The median interval between the diagnoses of pancreatic cancer and associated double primary tumors was 0.5 months. Overall survival (OS) of pancreatic cancer patients with associated double primary tumors was longer than those with pancreatic cancer only (median, 23.1 months vs. 17.0 months, p=0.002). Patients whose pancreatic cancers were resected before the diagnosis of metachronous tumors had a better OS than patients whose pancreatic cancer resected after the diagnosis of metachronous tumors (48.9 months and 13.5 months, p=0.001) or those whose pancreatic cancers were resected synchronously with non-pancreas tumors (19.1 months, p=0.043). The OS of pancreatic cancer patients with stomach (33.9 months, p=0.032) and thyroid (117.8 months, p=0.049) cancers was significantly better than those with pancreas cancer only (17.0 months).
Conclusion
About 8% of resected pancreatic cancers had associated double primary tumors, and those from the colorectum, stomach, lung, and thyroid were common. Patients whose pancreatic cancer was resected before the diagnosis of metachronous tumors had better OS than those resected after the diagnosis of metachronous tumors or those resected synchronously.

Citations

Citations to this article as recorded by

Laparoscopic Radical Total Gastrectomy and Pancreatosplenectomy for Synchronous Cancer of the Stomach and Pancreas
Motoki Ebihara, Kentoku Fujisawa, Shusuke Haruta, Hironori Uruga, Masaki Ueno
Cureus.2024;[Epub] CrossRef
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papillary mucinous tumor associated with ductal adenocarcinoma of the pancreatic tail
G.R. Setdikova, E.A. Stepanova, A.N. Verbovsky, A.V. Semenkov
Pirogov Russian Journal of Surgery.2024; (8): 57. CrossRef
Pancreatoduodenectomy after Ivor-Lewis Santi oesophagectomy with gastric tube reconstruction. An European multicentre experience
Alessandro D. Mazzotta, Pietro Addeo, Benedetto Ielpo, Michael Ginesini, Nicolas Regenet, Ugo Boggi, Philippe Bachellier, Olivier Soubrane
Surgical Oncology.2024; 57: 102144. CrossRef
The importance of hsa-miR-28 in human malignancies
Seyede Fatemeh Hosseini, Setareh Javanshir-giv, Hanieh Soleimani, Homa Mollaei, Farzad Sadri, Zohreh Rezaei
Biomedicine & Pharmacotherapy.2023; 161: 114453. CrossRef
Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
Takahiro Murokawa, Takehiro Okabayashi, Kenta Sui, Motoyasu Tabuchi, Jun Iwata
Surgical Case Reports.2022;[Epub] CrossRef
A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience
Moustafa S. Alhamadh, Rakan B. Alanazi, Sultan T. Algarni, Ahmed Abdullah R. Alhuntushi, Mohammed Qasim Alshehri, Yusra Sajid Chachar, Mohammad Alkaiyat, Fouad Sabatin
Current Oncology.2022; 29(7): 4941. CrossRef
Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review
Daniel Paramythiotis, Georgia Fotiadou, Eleni Karlafti, Ioanna Abba Deka, Georgios Petrakis, Elisavet Psoma, Xanthippi Mavropoulou, Filippos Kyriakidis, Smaro Netta, Stylianos Apostolidis
Diagnostics.2022; 12(11): 2709. CrossRef
Ergebnisse nach Pankreaseingriffen aus Sicht der Betroffenen: Versorgungsforschung der Selbsthilfegruppe „Arbeitskreis der Pankreatektomierten e. V.“
Ioannis Dimopoulos, Gabriele Meyer, Saleem Ibrahim Elhabash, Michele Sorleto, Carsten Gartung, Nils Ewald, Ulrich Klaus Fetzner, Lutz Otto, Friedhelm Möhlenbrock, Waldemar Uhl, Berthold Gerdes
Zeitschrift für Gastroenterologie.2021; 59(03): 214. CrossRef
An extremely atypical presentation of esophageal squamous cell carcinoma with pancreatic and hepatic metastases
Lei Zhang, Xin Long, Zheng-Nan Hu, Yu Wu, Jia Song, Bi-Xiang Zhang, Wei-Xun Chen
Medicine.2021; 100(20): e25785. CrossRef
Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis
Hironori Hayashi, Koji Amaya, Tomokazu Tokoro, Kosuke Mori, Shunsuke Takenaka, Yuya Sugimoto, Yuto Kitano, Toru Kurata, Shunsuke Kawai, Atsushi Hirose, Tomoya Tsukada, Masahide Kaji, Koichi Shimizu, Kiichi Maeda
Molecular and Clinical Oncology.2021;[Epub] CrossRef
A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef
Synchronous concomitant pancreatic acinar cell carcin and gastric adenocarcinoma: A case report and review of literature
Tian Fang, Ting-Ting Liang, Yi-Zhuo Wang, Hai-Tao Wu, Shu-Han Liu, Chang Wang
World Journal of Clinical Cases.2021; 9(28): 8509. CrossRef
A novel long non‑coding RNA TTN‑AS1/microRNA‑589‑5p/FOXP1 positive feedback loop increases the proliferation, migration and invasion of pancreatic cancer cell lines
Jing Zhao, Fang Wu, Jun Yang
Oncology Letters.2021;[Epub] CrossRef
Multiple primary gastrointestinal tumors of gastric, pancreatic and rectal origin; a case report
Abdullah Mohammed Aloraini, Hadeel Ayman Helmi, Nadia Abdulaziz Aljomah, Ahmad Mohmmed Zubaidi
International Journal of Surgery Case Reports.2021; 89: 106610. CrossRef
A Newly Developed Pancreatic Adenocarcinoma in a Patient with Advanced Thyroid Cancer under Long-Term Sorafenib Use
Min Ji Kim, Han-Sang Baek, Sung Hak Lee, Dong-Jun Lim
International Journal of Thyroidology.2021; 14(2): 175. CrossRef
Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression
Qing Han, Junhe Li, Jianping Xiong, Zhiwang Song
Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef
Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
Oronzo Brunetti, Giuseppe Badalamenti, Simona De Summa, Angela Calabrese, Antonella Argentiero, Livia Fucci, Vito Longo, Domenico Galetta, Pia Maria Soccorsa Perrotti, Rosamaria Pinto, Daniela Petriella, Katia Danza, Stefania Tommasi, Francesco Leonetti,
Cancers.2019; 11(6): 749. CrossRef

14,813 View
246 Download
17 Web of Science
17 Crossref

First
Prev
Page of 1
Next
Last

Search